Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.
OHE at HTAi 2018
29 May 2018
Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2018 conference in Vancouver, 1-5 June.
A New Online Tool for Creating Personal and Social EQ-5D-5L Value Sets
4 May 2018
OHE’s Prof Nancy Devlin has been collaborating on a new approach to creating personal and social EQ-5D-5L value sets, based on a web application.
New Publications: Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
18 April 2018
Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper…
Valuing Health at the End of Life: A Review of Stated Preference Studies in the Social Sciences Literature
9 April 2018
Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.
Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
4 April 2018
A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.
Value Frameworks: Value in Health Special Issue
29 March 2018
A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the…
Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
22 March 2018
A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.
OHE Lunchtime Seminar: Valuing Children’s Health for Economic Evaluation
15 February 2018
OHE Lunchtime Seminar with Oliver Rivero-Arias on Valuing Children’s Health for Economic Evaluation. 29 March 2018 12:00-2:00pm